title: Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.
abstract: BACKGROUND
  In lymph node-negative, hormone-positive, and Her2-negative breast cancer patients, the benefits of adding adjuvant chemotherapy to hormonal therapy continue to be debated, especially for low to intermediate grade and small tumors.
  
  
  METHODS
  Excluding patients with T4 disease, we retrospectively reviewed the records of patients with long-term follow-up at our center between 2003 and 2014. Among node-negative, hormone-positive and HER2-negative breast cancer patients, we compared two groups of patients: those given both chemotherapy (doxorubicin+cyclophosphamide) and hormonotherapy, and those prescribed hormonotherapy alone. The primary endpoints were progression-free (PFS) and overall survival (OS).
  
  
  RESULTS
  Overall, no difference was observed between these two treatment groups in either DFS or OS. However, for both outcomes, there was a trend towards improved DFS and OS favoring the hormone-only group.
  
  
  CONCLUSIONS
  In selected subgroups of breast cancer patients, administering adjuvant hormonal therapy alone seems to be at least as good if not better than combining hormonotherapy and chemotherapy.
authors.affiliation: Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.
authors.forename: Taner
authors.initials: T
authors.lastname: Babacan
authors.forename: Hakan
authors.initials: H
authors.lastname: Buyukhatipoglu
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.forename: Neyran
authors.initials: N
authors.lastname: Kertmen
authors.forename: Ali
authors.initials: A
authors.lastname: Suner
authors.forename: Furkan
authors.initials: F
authors.lastname: Sarici
authors.forename: Serkan
authors.initials: S
authors.lastname: Akin
authors.forename: Ozturk
authors.initials: O
authors.lastname: Ates
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Karakas
authors.forename: Alma
authors.initials: A
authors.lastname: Aslan
authors.forename: Omer
authors.initials: O
authors.lastname: Diker
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D012189:Retrospective Studies
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human